Literature DB >> 62724

Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines.

G Klein, J Zeuthen, P Terasaki, R Billing, R Honig, M Jondal, A Westman, G Clements.   

Abstract

Two EBV-negative lymphoma lines of human B-cell origin, BJAB and Ramos, were compared with altogether six of their in vitro EBV-converted, EBNA- and EBV-DNA-carrying sublines (four of Ramos and two of BJAB derivation). All converted lines closely resembled the parental line with regard to karyotype and HL-A and B antigen typing. Induction of EBV antigens (EA and VCA) by P3HR-1 virus superinfection was either similar in the converted and the negative lines, or somewhat increased in certain converted lines. These findings argue against a simple, virally determined repressor model and emphasize the role or cellular controls in restricting the EBV cycle in virus-carrying B-lymphocyte lines of human origin. IUdR inducibility varied in the different converted lines. There was a possible relationship between average number of EBV-genome equivalents per cell and inducibility. Converted sublines did not differ from the original negative lines with regard to surface immunoglobulin and Fc receptors. There was a dramatic increase in complement-consuming ability, however, following EBV conversion. Among the EBV-positive lines, there was a linear relationship between complement-consuming and EBV-receptor activity, the latter measured by a quantitative absorption test.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 62724     DOI: 10.1002/ijc.2910180513

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  S Nikiforow; K Bottomly; G Miller
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Epstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants.

Authors:  A Marchini; R Longnecker; E Kieff
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  A selectable marker allows investigation of a nontransforming Epstein-Barr virus mutant.

Authors:  A Marchini; J I Cohen; F Wang; E Kieff
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

4.  Refinement of HLA gene mapping with induced B-cell line mutants.

Authors:  B Spring; C Fonatsch; C Müller; G Pawelec; J Kömpf; P Wernet; A Ziegler
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

5.  Purification and biochemical characterization of the Epstein-Barr virus-determined nuclear antigen and an associated protein with a 53,000-dalton subunit.

Authors:  J Luka; H Jörnvall; G Klein
Journal:  J Virol       Date:  1980-09       Impact factor: 5.103

6.  Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain.

Authors:  P Trivedi; P Spinsanti; L Cuomo; M Volpe; K Takada; L Frati; A Faggioni
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Identification of multiple Epstein-Barr virus-induced nuclear antigens with sera from patients with rheumatoid arthritis.

Authors:  T B Sculley; P J Walker; D J Moss; J H Pope
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

8.  Interferon-induced 56,000 Mr protein and its mRNA in human cells: molecular cloning and partial sequence of the cDNA.

Authors:  J Chebath; G Merlin; R Metz; P Benech; M Revel
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

9.  Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells.

Authors:  M Fellous; U Nir; D Wallach; G Merlin; M Rubinstein; M Revel
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

10.  Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells.

Authors:  F Wang; A Marchini; E Kieff
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.